AVR
Anteris Technologies Global Corp.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-1394.34
P/S
105.77
EV/EBITDA
-2.08
DCF Value
$-1.37
FCF Yield
-39.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.3%
Operating Margin
24.4%
Net Margin
-4921.3%
ROE
-528.4%
ROA
-410.5%
ROIC
21.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $310.0K | $-29.2M | $-1.24 |
| FY 2025 | $1.9M | $-94.2M | $-4.00 |
| Q3 2025 | $429.0K | $-22.2M | $-0.94 |
| Q2 2025 | $618.0K | $-20.8M | $-0.89 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
AU
Exchange
NASDAQ
Beta
0.55
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also devlops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. was incorporated in 1999 and is based in Toowong, Australia.